Sun Pharmaceutical Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the US For Potential COVID-19 Treatment

Sun Pharmaceutical Industries announced that it has donated 2.5 million hydroxychloroquine sulfate tablets for use in the United States. Sun Pharma is seeking to enable health care experts meet the growing patient demands for this product as they assess its potential to treat COVID-19 through clinical trials.

“At Sun Pharma, we are resolute in our purpose to help people live healthier lives and stand united in our global fight against COVID-19,” Abhay Gandhi, CEO, Sun Pharma, North America, said in a company news release. “We are working with supply chain partners and wholesalers to help ensure swift delivery to areas where it will provide the most benefit as the clinical trials progress.”

Hydroxychloroquine sulfate tablets manufactured by Sun Pharma are approved by the FDA for the treatment of a range of conditions including malaria, lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is not currently approved for use in the treatment of COVID-19; however, it is currently under investigation as a possible treatment option for coronavirus.